The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
Published ·
Keep reading
